NHL diagnoses comparatively high among solid organ transplant patients

According to a study in the Journal of the American Medical Association people who receive solid organ transplants have twice the risk of developing cancer in their lifetimes, with an especially high rate of incidence among this population for developing cancers such as non-Hodgkin's lymphoma.

Researchers with the US National Cancer Institute examined data from over 175,000 transplants between 1987 and 2008. They found 10,656 cancer diagnoses during follow-up, or a figure that was about double the general population.

Unfortunately, researchers could not identify if certain organ transplants created a greater risk for cancer. However, they were able to determine that cancers of the lung, liver, kidney, and non-Hodgkin's lymphoma accounted for 43% of those cancers, compared to just 21% of cancers in the general population.

The link to NHL might have something to do with the need for transplant patients to take immunosuppressive medications, although that is merely speculation on the part of researchers.

Source:
Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891-1901

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap